by mdehxaba | Mar 19, 2026 | News
Masked T‑cell engagers: cancer immunotherapies for the future? A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own...
by mdehxaba | Oct 23, 2025 | News
The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...
by mdehxaba | Aug 20, 2025 | News
The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...
by mdehxaba | Feb 6, 2025 | News
The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...
by mdehxaba | Oct 15, 2024 | News
The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...
